Pharvaris reports financial results for the third quarter ended 30 September 2022, and provides a business update:
“The results of the RAPIDe-1 study affirm our confidence in our clinical development program in HAE,” says Berndt Modig, CEO of Pharvaris. “Pharvaris is fully committed to resolving the clinical holds on PHA121 in the U.S., and we appreciate the opportunity to meet with the FDA in the recent Type A meeting and to work with the agency on the next steps. To date, the regulatory status for our studies outside the U.S. remains unchanged. Top-line data from CHAPTER-1, a proof-of-concept study of PHVS416 for the prophylactic treatment of HAE, is anticipated in the second half of 2023. Pharvaris has a strong financial position and will continue to operate with a disciplined approach as we aspire to bring best-in-class oral therapies to the HAE community.”
(Source: Pharvaris)
